"Closed-Loop" O₂-Economizer Induced In Situ Therapeutic Vaccine against Hypoxic Tumors

Area of Science:

• Biomedical Engineering
• Cancer Immunotherapy
• Nanomedicine

Background:

• Therapeutic tumor vaccines are promising anticancer strategies, with in situ vaccines showing potential in cancer immunotherapy.
• Tumor hypoxia often limits the efficacy of in situ vaccine generation by reducing tumor antigen production.
• Novel approaches are needed to overcome the hypoxic tumor microenvironment and enhance cancer immunotherapy.

Purpose of the Study:

• To design and evaluate a closed-loop mitochondrial oxygen-economizer (TPCA) for enhanced phototherapy-driven in situ vaccines.
• To investigate TPCA's ability to alleviate tumor hypoxia and improve photodynamic therapy (PDT) efficacy.
• To explore the underlying mechanisms of TPCA-mediated antitumor responses.

Main Methods:

• TPCA was synthesized by integrating a photosensitizer (CyI) and mitochondrial inhibitor (atovaquone) into a PAMAM dendrimer.
• Mitochondrial targeting was achieved using (3-propylcarboxyl) triphenylphosphine bromide (TPP).
• In vitro and in vivo studies assessed TPCA's effect on tumor hypoxia, PDT efficacy, and immune responses.

Main Results:

• TPCA successfully restricted tumor cell respiration, reducing hypoxia and providing oxygen for enhanced cyanine dye-mediated PDT.
• TPCA-boosted PDT induced immunogenic cancer cell death, increasing damage-associated molecular patterns (DAMPs) exposure.
• TPCA treatment promoted T cell recruitment into the tumor microenvironment, enhancing in situ vaccine effects and systemic antitumor responses.

Conclusions:

• TPCA effectively overcomes tumor hypoxia, enhancing PDT-induced in situ vaccines for direct tumor ablation.
• The developed oxygen-economizer strategy elicits immunogenic cell death and reprograms the immunosuppressive tumor microenvironment.
• This approach offers innovative strategies for treating primary, metastatic, and recurrent tumors.